How to Optimize NSCLC Surgical Outcomes for Patients With Frailty
Presenters at the 2025 ASCO Annual Meeting shared how clinicians can optimize surgical outcomes for frail patients with locally advanced NSCLC.
Jul 15, 2025
MEETING BRIEF
ASCO 2025 – NSCLC
The latest news from ASCO 2025 focusing on NSCLC including abstracts, features, and helpful conference information.
Histologic Subtype May Inform Immunotherapy Strategy in mNSCLC Without Targetable Mutations
Histologic Subtype May Inform Immunotherapy Strategy in mNSCLC Without Targetable Mutations
Analyses suggest squamous and nonsquamous tumors differ in immunobiology and may respond differently to the addition of LAG-3 inhibitors to PD-1–based therapy.
In NSCLC, Complete Blood Count a Promising Prognostic Biomarker
In NSCLC, Complete Blood Count a Promising Prognostic Biomarker
A new complete blood count-based score predicted worse outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
In NSCLC, Personalized Radiotherapy Effective for Ultra-Central Tumors
In NSCLC, Personalized Radiotherapy Effective for Ultra-Central Tumors
Tailored radiotherapy with nonuniform target compromises and stringent constraints delivered excellent local control and low toxicity for ultra‑central NSCLC.
A Call to Optimize First-Line NSCLC Treatment Strategies
A Call to Optimize First-Line NSCLC Treatment Strategies
Nearly 1 in 5 patients with NSCLC and targetable mutations never received second‑line therapy, highlighting the urgency of optimizing first‑line treatments.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
